Home › Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol
 

Keywords :   


Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

2015-03-22 06:59:40| Biotech - Topix.net

Amgen today announced that an application seeking marketing approval of RepathaTM for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labour and Welfare in Japan. Repatha is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.

Tags: of high japan marketing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
05.11Tropical Storm Rafael Wind Speed Probabilities Number 6
05.11Tropical Storm Rafael Public Advisory Number 6
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 6
05.11Why colouring clothes has a big environmental impact
05.11Atlantic Tropical Weather Outlook
More »